Kornimate/medical-research-clean huggingface dataset:
a nutritional intervention for migraines

Conditions: Migraines

Summary: the purpose of the study is to assess whether, in individuals with migraines, a low-fat, vegan diet improves pain more effectively than a control supplement or a placebo. the principal measures are pain as measured by visual analog scale (vas) and the change in migraines frequency. the study duration is 36 weeks.

preliminary evidence suggests that low-fat, vegetarian diets and certain nutritional supplements can help reduce pain and also reduce the need for pain medications for some people. we will ask about 100 people to participate. all of them will get a low-fat, vegan diet and a nutritional supplement (mixture of omega-3 oils and vitamin e or a placebo), although some will get the diet first, and others will get the supplement first. this order in which they will get the diet and the supplement will be determined randomly, that is, by chance (like the toss of a coin). the principal measures are pain as measured by visual analog scale (vas)and the change in migraines frequency.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of migraine, as defined by the criteria of the second edition of the international classification of headache disorders18 * at least 5 attacks fulfilling criteria the criteria below * headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) * headache has at least two of the following characteristics: * unilateral location * pulsating quality * moderate or severe pain intensity * aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs) * during headache at least one of the following: * nausea and/or vomiting * photophobia and phonophobia * not attributed to another disorder 2. migraines occurring at least twice per month, on average. 3. age at least 18 years 4. ability and willingness to participate in all components of the study 5. willingness to be assigned to either the diet group or supplement group 6. migraine medications unchanged within last 6 weeks. exclusion criteria: 1. \< 18 years of age 2. alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use 3. use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion) 4. pregnancy 5. unstable medical or psychiatric illness 6. likely to be disruptive in group sessions (as determined by research staff) 7. already following a low-fat, vegan diet 8. lack of english fluency 9. inability to maintain current medication regimen 10. inability or unwillingness to participate in all components of the study

Keywords: migraines diet, vegetarian diet, fat-restricted pain
study of stereotactic radiotherapy for breast cancer

Conditions: Breast Cancer

Summary: this is a phase ii trial of preoperative stereotactic radiation to the breast for low risk breast cancer.

this is a single arm phase ii study design, evaluating the pathologic response (primary endpoint) as well as toxicity, cosmetic outcome, quality of life, and translational correlates (secondary endpoints) to pre-operative stereotactic body radiotherapy (sbrt) to intact breast tumors in patients with hormone-receptor positive early stage breast cancer.

Eligibility criteria:
inclusion criteria: * female sex * age \> or = to 50 years of age * invasive ductal carcinoma * clinically and radiographically t1 tumor * clinically node negative * clearly demarcated tumor on magnetic resonance imaging (mri), as determined by treating physician (mri may be done after enrollment if not done prior) * planning breast conserving surgery including sentinel node biopsy * ≥10% expression of er and/or pr * her2- using the current college of american pathologists guidelines * post-menopausal * willing and able to provide informed consent exclusion criteria: * medical conditions that may increase risk for poor cosmetic outcome (i.e. lupus, rheumatoid arthritis, scleroderma * pure dcis without invasive cancer * patients who have received or will be receiving neoadjuvant systemic therapy, endocrine therapy, or targeted agents * breast implant in the involved breast unless the implant will be removed prior to initiation of study treatment * positive pregnancy test * subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement. * unable to meet dosimetric constraints due to tumor location and/or patient anatomy * planning mastectomy * unable to tolerate prone positioning

Keywords: early stage low risk
molecular breast imaging (mbi) in patients with suspected ductal carcinoma in situ (dcis)

Conditions: Breast Cancer

Summary: in this research study, the investigators are testing a new type of breast camera, called molecular breast imaging, to see if it can find tumors in the subject's breast.

patients who are suspected to have dcis based on mammographic findings will be invited to participate in this study. the investigators plan to recruit 200 patients who are scheduled to undergo a breast biopsy for a breast lesion considered suggestive or highly suggestive of dcis as determined by a radiologist specializing in breast imaging. each patient will have a suspicious area of calcification on mammography of extent \< 3 cm, or a non-focal area of abnormality on ultrasound or mri that is scheduled for evaluation by biopsy. each patient will undergo an mbi study immediately prior to biopsy. the study coordinator will approach these patients and inform them of the research project. if they are interested in participating, informed consent will be obtained and the patient will be scheduled for the mbi study prior to the breast biopsy.

Eligibility criteria:
inclusion criteria: * women with a breast lesion suspicious for dcis who are scheduled for a stereotactic breast biopsy. * lesion must be considered suggestive or highly suggestive of malignancy according to the breast imaging reporting and data system atlas criteria (birads 4 or 5). * women between 25 and 90 years of age. exclusion criteria: * unable to understand or sign a consent form. * pregnant or lactating. * physically unable to sit upright and still for 30-40 minutes.

Keywords: mbi molecular breast imaging breast cancer dcis breast calcifications microcalcifications
newborn abdominal massage to prevent hyperbilirubinemia

Conditions: Newborn Jaundice

Summary: the proposed study will incorporate an intervention previously un-studied in the us healthcare setting for prevention of hyperbilirubinemia


Eligibility criteria:
inclusion criteria: * newborn admitted to the well newborn/postpartum care unit at uc davis medical center * less than 48 hours of age at enrollment exclusion criteria: * infant has already received phototherapy * mother/birthing person is incarcerated * infant unexpected to discharge into parental care * parental inability to speak or read in english * infant without parent rooming-in with them in the hospital

Keywords: newborn massage
pringle manoeuvre versus portal vein clamping for liver resection

Conditions: Liver Metastasis

Summary: liver resection is an operation to remove the diseased part of the liver. the liver is supplied by two vessels, the hepatic artery and the portal vein supplying 25% and 75% respectively of the total blood flow with 50% oxygen from each vessel. during liver resection it is standard practice to clamp both vessels(pringle's manoeuvre), so as to avoid bleeding. clamping both the vessels deprives the unaffected liver from nutrients required for survival. reinstating the blood supply causes further damage by pouring harmful substances into the liver, which accumulate during the clamping. we hypothesize that not clamping the oxygen rich hepatic artery will cause less damage to the liver. our aim is to compare the pringle manoeuvre with portal vein clamping, to identify if the latter will result in less tissue injury and thereby fewer complications. initially we aim to conduct a pilot study. the main objective is to ensure that patients can be successfully recruited and that data capture is complete. the secondary outcomes will be development of infective complications by 30 days following surgery, bleeding and blood transfusion requirements, heart/chest complications, recovery of liver functions, growth of remnant liver, death within 30 days following surgery, length of high dependency unit/hospital stay and quality of life at 3 months after surgery. there is published literature on the safety of this method and in the event of any intraoperative problems, the procedure will be converted to the standard pringle manoeuvre. the liver unit at st james's university hospital has four surgeons performing around 270 liver cancer resections per year, of which nearly 160 are for bowel cancer spread. considering the team's experience in research and liver surgery, we believe it is well placed to conduct the trial in a safe and efficient manner.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * undergoing liver resection for crlm * portal venous clamping as considered appropriate * participating patients should be able to understand the study objectives and be able to give written consent * able to complete study questionnaire exclusion criteria: * patients having simultaneous bowel and hepatic surgery * patients participating in other trials that could impact the outcomes measures being recorded * patients who are pregnant * patients taking immunosuppressive medication
study evaluating inotuzumab ozogamicin [cmc-544] administered in combination with rituximab in subjects with non-hodgkin's lymphoma (nhl)

Conditions: B-Cell Lymphoma

Summary: the purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[cmc-544\] in combination with rituximab in subjects with follicular, diffuse large b-cell, or mantle cell nhl.


Eligibility criteria:
inclusion criteria: * subjects with cd20 and cd22-positive, follicular or diffuse large b-cell nhl who have not responded or progressed after 1 or 2 prior therapies; or subjects with cd20 and cd22-positive intermediate/aggressive nhl (diffuse large b-cell, mantle cell, transformed follicular or follicular grade 3b nhl) who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy. * prior therapy must contain at least one course of rituximab therapy, as single agent or in combination. * measurable disease. exclusion criteria: * subjects who are candidates for other potentially curative therapies. * subjects must not have received previous radioimmunotherapy. * subjects who have undergone a prior bone marrow transplantation within the last 6 months.

Keywords: lymphoma nhl
"eye" education for parents and myopia control in children

Conditions: Children; Health Education; Anxiety

Summary: this is a randomized controlled trial aimed to explore the effect of behavioral interventions based on doctors' and nurses' health education on the onset and development of myopia in children's. participants were randomly assigned to one of two groups: eye health intervention, or the control group. intervention group's parents would reveive eye health education in response to their children's myopia progression at baseline, 1 month, 3 months, and 6 months, while the control group did not receive any. visual acuity, cycloplegic refraction, axial length, strengths and difficulties questionnaire, and generalized anxiety disorder 7-item scale were the main outcomes and measures.

after doctors' and nurses' education, parents would keep a diary to regulate the children's "sedentary", "sunshine", "sleep", "screen", and "stress" that is, the "5s" eye education. to urging parents pay attention to the children's eye behavior every day, and targeted to children "eye" education to delay the occurrence and development of myopia and reduce the incidence of high myopia.

Eligibility criteria:
inclusion criteria 1. children aged 5-17; 2. removing flexible lenses for at least 1 week, flexible astigmatism and hard lenses for at least 3 weeks, orthokeratology lenses for at least 3 months; 3. best corrected visual acuity of either eye were all ≥ 1.0; 4. the range of myopia in either eye was -15 d ≤ se ≤ +2.0 d; 5. astigmatism of either eye less than -5.0 d; 6. anisometropia ≤ -1.5 d; 7. there was no active ocular inflammatory diseases; no obvious corneal cloud or macula, anormal corneal topography, and no tendency of keratoconus. 8. intraocular pressure of either eye is of 10 to 21 mmhg; 9. on the basis of full understanding, children and their guardians sign the informed consent; exclusion criteria: 1. amblyopia: best corrected visual acuity (bcva) of either eye less than 1.0 for children over 6 years old; 2. active ocular inflammatory diseases, such as uveitis and other inflammatory diseases; 3. secondary myopia, genetic disease or connective tissue- related myopia; 4. moderate or severe ptosis; 5. congenital cataract, glaucoma; 6. other fundus diseases other than myopic related fundus lesions; 7. intraocular or refractive surgery history; 8. the refractive medium is turbid, and it is impossible to take a clear fundus image; (9)unable to cooperate with fundus image shooting and other examination; (10)do not receive cycloplegia or have contraindications; (11)poor overall condition, unable to follow up for a long time; (12)the subject refuses to participate in the research; (13)other cases in which the researcher judges that it is not suitable for participation in the study.
dahanca 35: proton versus photon therapy for head-neck cancer

Conditions: Head-and-neck Cancer

Summary: patients with squamous cell carcinoma of the pharynx or larynx and an anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia are randomized to proton or photon radiotherapy (2:1)

dahanca 35 is two parallel conducted, but separate randomized studies, within the same trial (dahanca 35d and dahanca 35x) by the danish head-neck cancer study group (dahanca). in patients with squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy a proton and a photon doseplan is prepared. if proton radiotherapy reduces the anticipated absolute risk of dysphagia \>= grade 2 (dahanca scale, dahanca 35d) or severe xerostomia \>= grade 4 (eortc head-neck 35, dahanca 35x) more than 5%, the patient is randomised to either proton therapy or photon therapy, 2:1. the anticipated risk of xerostomia and dysphagia is estimated using normal-tissue complication models (ntcp). patient are analysed according to the primary endpoint (dysphagia and/or xerostomia) after which they were enrolled. dahanca 35d is expected to enroll 360 patients and dahanca 35x 240 patients (in total 600 patients).

Eligibility criteria:
inclusion criteria: * patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent * a predicted clinical significant reduction in the risk of any of the two primary endpoints (\>= grade 2 observer-rated dysphagia or grade 4 patient-reported xerostomia) after proton therapy compared to photon therapy based on comparison of the individual patient dose plans * no current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer * informed consent as required by law * above 18 years of age exclusion criteria: * patient with cancers of the glottic larynx (stage i/ii), skull base, sino-nasal area, unknown primary tumor and prior malignancies. * patients with contraindications for proton therapy. per october 2020, this includes pacemakers, implanted defibrillators and tracheostomy * inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic * distant metastasis * previous radiotherapy of the head and neck * previous surgery for the primary cancer with curative intent

Keywords: proton radiotherapy dahanca
pediatric study to evaluate risk of developing essential fatty acid deficiency when receiving clinolipid or standard-of-care lipid emulsion

Conditions: Essential Fatty Acid Deficiency (EFAD)

Summary: this will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with clinolipid or standard of care for up to 90 days to develop essential fatty acid deficiency (efad). additionally, this study design will evaluate the safety and efficacy of using clinolipid in a pediatric population.


Eligibility criteria:
inclusion criteria: 1. patients and/or their legal representative must be able to understand the study and voluntarily sign the icf 2. patients age \<18 years 3. patients who are able to adhere to protocol requirements 4. patients who are expected to require pn for at least 7 days 5. premature infants (\<36 weeks of gestation) require at least 80% pn to meet nutrition requirements at study entry; full term infants and children require at least 70% pn to meet nutrition requirements at study entry exclusion criteria: 1. patients who are not expected to survive hospitalization or with a severe illness with foreseeable intercurrent events that could jeopardize the patient's participation in the study 2. patients with a known hypersensitivity to lipid emulsion, egg or soybean proteins, or any of the active substances, excipients, or components of the container 3. patients with a diagnosis of shock, renal failure requiring dialysis, or severe metabolic acidosis (eg, ph \ 16 meq/l) 4. patients with hemodynamic instability as judged by the investigator 5. patients with uncorrected metabolic disorders (eg, diabetes) or liver disease including cholestasis 6. patients with severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (triglyceride \>400 mg/dl) 7. patients who are unable to tolerate the necessary laboratory monitoring 8. patients who have a new and active infection (as assessed by the investigator) at time of initiation of study treatment 9. patients who are enrolled in another clinical trial involving an investigational agent 10. patients who were treated with iv lipids within 48 hours of randomization into the study

Keywords: essential fatty acids (efa) parenteral nutrition clinolipid/clinoleic parenteral nutrition associated cholestasis (pnac) parenteral nutrition associated liver disease (pnald) intestinal failure associated liver disease (ifald) phytosterols intralipid infants/preterm infants fads1 and fads2 short bowel syndrome cancer nutrition olive oil emulsion soybean oil emulsion
the association between siri and pod in older patients

Conditions: Postoperative Delirium; Elderly; Surgery

Summary: postoperative delirium (pod) remains one of most common complication in elderly patients receiving surgery, which is characterized by acute and fluctuating change in the level of cognition and consciousness. previous studies have shown that surgery and anesthesia-induced acute peripheral inflammation and neuroinflammation may lead to delirium after surgery. systemic inflammation response index (siri) is a more easily accessible and comprehensive inflammation marker derived from monocyte, neutrophil, and lymphocyte count, which has been investigated to assess the prognosis of cancer and infectious diseases. however, the relationship between siri and pod has yet to be investigated.


Eligibility criteria:
inclusion criteria: * hospital stay of at least 3 days * more than or equal to 65 years old * elementary education or above * able to communicate * american society of anesthesiologists (asa) physical status i-iii * mini-mental state examination (mmse) scores ≥ 22 points exclusion criteria: * preoperative delirium * severe mental diseases * autoimmune-illness, chronic infectious diseases, nervous system diseases and malignancies
study of an emergency department-based intervention to reduce alcohol misuse in older adults

Conditions: Alcohol Abuse

Summary: this is a randomized trial to assess the value of an emergency department-based intervention to reduce hazardous alcohol use among older adults. we hypothesize that the intervention will result in a 25% reduction in the prevalence of hazardous alcohol use while the control group will only have a 5% reduction.

the goal of this project is to perform a pilot, randomized, controlled trial of a brief intervention and referral for treatment among older adults in the emergency department (ed) with alcohol misuse. the pilot data would then be used to design a larger study. the intervention for this trial will consist of a brief negotiation interview (bni) with a stratified referral for further treatment, compared with usual care. the bni is a standardized, well-described intervention that has been implemented in a broad range of clinical settings but has not been specifically tested in older adults in the ed. following the bni, we will provide a referral for further care for the patient that is stratified by severity of alcohol misuse. patients with hazardous or harmful alcohol use will follow-up with a primary care physician; patients with alcohol abuse or dependence will follow-up with an outpatient alcohol and substance abuse program; those at risk for complicated withdrawal will be recommended for inpatient treatment. in all cases we will contact the referral physician to help transition the patient's care, and ensure the patient receives a consistent message regarding their alcohol use across the different care settings.

Eligibility criteria:
inclusion criteria: * age 65 and older * receiving care in the emergency department * hazardous alcohol use, defined as reporting drinking more than 7 drinks per week on an average week during the three months prior to the visit, and whether they have consumed more than three drinks on any given occasion. exclusion criteria: * prisoner * psychosis or psychiatric hold * nursing home * life-threatening condition * current hospice care

Keywords: alcoholism dangerous behavior aged emergency medicine
preoperative concurrent chemoradiotherapy for locally advanced gastroesophageal junction or upper gastric adenocarcinoma

Conditions: Gastroesophageal Junction Adenocarcinoma

Summary: preoperative chemoradiotherapy(crt) had been introduced in the comprehensive treatment of gastroesophageal junction and upper gastric cancers in the decade.according to some researches,crt had shown its good curative effects in local control and prolonged overall survival.however,the optimization scheme for crt and its influence to surgery remains controversial.meanwhile,there were many design flaws in the past few research,such as the lack of adjuvant chemotherapy,the insufficiency in lymphnodes dissection.we decided to carry out the trial,eliminating all the bias as far as we can,to illustrate the efficacy and safety of crt.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of the gastroesophageal junction. * clinical stage diagnosed by endoscopic ultrasound(eus) or computed tomography(ct) as t3-4nxm0 tumors,according to american joint committee on cancer (ajcc) 7th edition. * eastern cooperative oncology group (ecog) performance status≤2. * informed consent obtained. exclusion criteria: * combined with other malignant tumors. * eastern cooperative oncology group (ecog) performance status\>2. * combined with severe organ dysfunction. * pregnancy

Keywords: preoperative concurrent chemoradiotherapy neoadjuvant chemoradiotherapy gastroesophageal junction adenocarcinoma